Robert S. Galvin, MD [Moderator]

Dr. Robert Galvin is the Chief Executive Officer of Equity Healthcare (EH), which oversees the management of health care for firms owned by private equity companies. The focus is on using purchasing power to create innovative ways to achieve higher value health care, through improved population health, clinical quality and delivery system reforms. Currently, EH encompasses over 30 companies with healthcare spending exceeding $1.5B annually. 

Before joining Blackstone, Dr. Galvin was Executive Director of Health Services and Chief Medical Officer for General Electric (GE) for fifteen years, where he was in charge of the design, financial and clinical performance of GE’s health programs. He was also responsible for health policy strategies affecting employees. Dr. Galvin is a nationally recognized leader in the areas of market-based health policy and financing, quality measurement and payment reform. His work has been widely published in the New England Journal of Medicine and Health Affairs and he was a co-founder of the Leapfrog Group and founder of two other groups, Bridges to Excellence and Catalyzing Payment Reform, all innovative non-profits that have helped drive the quality agenda.

Dr. Galvin is a member of the Institute of Medicine and sits on the IOM’s Board on Health Care Services. He is also on the Board of Directors of the National Quality Forum and a member of the National Advisory Council for the Agency for Healthcare Research and Quality (AHRQ). Dr. Galvin is Professor Adjunct of Medicine and Health Policy at Yale. His work has received awards from the National Business Group on Health, the Healthcare Financial Management Association and the National Coalition for Cancer Survivorship. He is a fellow of the American College of Physicians. 

Andrew Bhak   

Andrew Bhak is a Managing Director in Morgan Stanley’s Global Healthcare Investment Banking Group, where he leads the firm’s Healthcare Services/Providers practice.  He has advised on and executed many notable corporate finance transactions, including: HCA's $4.3BN IPO; CD&R's $3.2BN Acquisition & Related Financing of Emergency Medical Services; Kindred Healthcare's $1.3BN Acquisition & Related Financing of RehabCare Group; Quest Diagnostics' Acquisitions & Related Financing of Athena Diagnostics and Celera Corp; and US Oncology's $2.16BN sale to McKesson, Carlyle’s $6.3BN Acquisition of Manor Care, among others. 

Prior to his career as an investment banker, he spent over 10 years as a senior equity research analyst covering the healthcare facilities and services sector, including at Morgan Stanley. Before coming to Wall Street, Andrew was with the Health Financing Group of GAO, the investigative arm of Congress, where he worked on a range of Medicare and Medicaid issues.   

Andrew serves on the Board of Directors for the National Emphysema Foundation.

Marina Bozilenko

Marina Bozilenko, Head of Biotech & Pharma, Managing Director, joined William Blair & Company in 2010. Ms. Bozilenko brings to the firm over 20 years of investment banking and other healthcare industry expertise, including raising more than $12 billion in capital and executing numerous M&A transactions. Most recently, she was a principal at Kidd & Company, a private-equity firm, and prior to that, worked at Bear, Stearns & Co. Inc. as a senior managing director in the healthcare group. Before that, Ms. Bozilenko was at Banc of America Securities as a managing director and head of biotechnology, and Vector Securities International, where she was a partner. She received her B.A. in molecular biology and M.A. in economic history from the University of Chicago.

Michael Dal Bello

Michael Dal Bello is a Managing Director in the Corporate Private Equity Group. Since joining Blackstone in 2002, Mr. Dal Bello has been involved in analyzing numerous investments in the healthcare, retail, communications and general industrial sectors. Before joining Blackstone, Mr. Dal Bello was an Associate at Hellman & Friedman where he was involved with the analysis and execution of private equity investments in the media and professional services sectors. Prior to that, Mr. Dal Bello worked as a strategic consultant at Bain & Company and also was a Research Associate at the China Center for Economic Research in Beijing as a Luce Scholar. Mr. Dal Bello received a BA in International Relations and a BS in Finance from the Wharton School of the University of Pennsylvania where he graduated summa cum laude and was elected to Phi Beta Kappa. Mr. Dal Bello was selected as a Thouron Scholar to attend Oxford University where he received an MA.   Mr.  Dal Bello received an MBA from Harvard Business School. 

He currently serves on the Board of Directors of Alliant Insurance, Apria Healthcare Group, Biomet, Catalent Pharma Solutions, Emdeon, Team Health, and Vanguard Health Services. 

Adam Feuerstein

Adam Feuerstein is a senior columnist for TheStreet, where he covers the biotechnology and pharmaceutical sectors. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Mr. Feuerstein rejoined TheStreet.com in 2007. He has been a business journalist for 22 years. Prior to his work at TheStreet, Mr. Feuerstein wrote about Internet startups and business software for Upside.com and commercial real estate and technology for the San Francisco Business Times. 

Sara Nayeem, M.D., is a Principal at New Enterprise Associates (NEA), a diversified venture capital firm with over $11 billion in committed capital.  Sara joined NEA's healthcare team in January 2009 and focuses on investments in biopharmaceutical companies.  She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has also been involved in NEA’s investment in 3-V Biosciences and Prosensa.  In addition, she has assisted with management of several of NEA's publicly traded portfolio companies, including Targacept, Amicus, and Inhibitex (acquired by Bristol-Myers Squibb).  Prior to joining NEA, Sara was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions.  Previously, she worked as an Investment Banking Analyst at Morgan Stanley.  She has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration.

Sara concurrently earned her M.D. (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar.  She received her AB (magna cum laude) in Biological Sciences from Harvard University.  Sara serves as a volunteer through Junior League and the Higher Achievement Program and is a working group member for BioHealth Innovation, an innovation intermediary in central Maryland.